MAO-B inhibitors

MAO-B inhibitors

Inhibitors of the enzyme monoamine oxidase B. MAO-B helps break down dopamine; inhibiting it prolongs the action of dopamine in the brain. Selegiline is an MAO-B inhibitor.
Mentioned in: Parkinson Disease
References in periodicals archive ?
Results show that the tested substances are powerful selective MAO-B inhibitors, yet with the reversible type of inhibition typical of natural substances and plausibly devoid of any significant side effects.
A recent study confirmed the ability of the Klamin[R] extract to cross the blood brain barrier, not only to stimulate through its PEA and MAO-B inhibitor content the brain dopaminergic activity and cascade, enhancing learning ability and attention in mice, but also to reduce, thanks to its AFA-PC and other antioxidants, the level of lipoperoxidation in mice brain (Sedriep et al.
A number of MAO-B inhibitors used in the clinical setting for treating Parkinson's disease have unwanted side effects.
The clinical impact of MAO-B inhibitors on Parkinson's symptoms was small, and almost all patients required the addition of levodopa to the treatment regimen after 3 or 4 years.
MAO-B inhibitors thus help improve the symptomatic motor effects of PD.
Agents such as the dopamine agonists, COMT inhibitors and MAO-B inhibitors can assist in addressing these.
Depression in patients with dementia can be treated with selected tricyclics, MAO-B inhibitors, and selective serotonin reuptake inhibitor medications.
Increasing use of MAO-B inhibitors is mostly attributed to Azilect, which demonstrated in the ADAGIO Phase III trial in early PD patients the ability to retard disease progression in addition to providing mild symptomatic relief from motor systems.
Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss PC, Kyburz E, Imhof R (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.
Selective MAO-B inhibitors, like Azilect([R]), do not generally interfere with tyramine breakdown and elimination at recommended doses.
It differs from earlier propargylamine MAO-B inhibitors in its chemical structure, its greater potency and lack of amphetamine metabolites.